<DOC>
	<DOCNO>NCT00883896</DOCNO>
	<brief_summary>The primary objective study assess safety efficacy different dose regimen ILV-094 compare placebo , administer subcutaneously subject active rheumatoid arthritis take methotrexate .</brief_summary>
	<brief_title>Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Meets American College Rheumatology ( ACR ) 1987 revise criterion classification Rheumatoid Arthritis ( RA ) least 6 month prior screen Active RA time screen baseline consist &gt; = 5 swell &gt; = 5 tender joint ( 28joint count ) least 1 follow screening : Creactive protein &gt; = 10 mg/L Erythrocyte Sedimentation Rate &gt; = 28 mm/h Must receive methotrexate least 12 week , stable route dose ( 25 mg weekly ) least 8 week prior baseline visit . Subjects rheumatic disease Cancer history cancer ( cutaneous basal cell carcinoma squamous cell carcinoma situ cervical cancer ) Any prior use B celldepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>ACR</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Interleukin-22</keyword>
</DOC>